Health ❯ Healthcare ❯ Pharmaceuticals ❯ Drug Development

Novo Nordisk

Novo Nordisk’s Oral Semaglutide Lowers HbA1c in Teens in Pivotal Trial

The positive result sets up pediatric filings in both regions in the second half of 2026.

India Tightens Oversight of GLP-1 Drugs as Semaglutide Generics Proliferate

Novo’s CagriSema Falls Short of Lilly’s Tirzepatide in 84-Week Head‑to‑Head Trial

CagriSema Beats Semaglutide on HbA1c and Weight at 68 Weeks in Type 2 Diabetes Trial

Novo Nordisk Launches Wegovy Weight‑Loss Pill in U.S. at $149 Starter Price

Novo Nordisk’s Oral Semaglutide Fails to Slow Alzheimer’s in Dual Phase 3 Trials

Lilly’s Orforglipron Pill Hits Phase 3 Goals and Outperforms Oral Semaglutide in Diabetes Study

Novo Nordisk Launches Wegovy Weight-Loss Drug in India